ReviewFrontiers in pharmacology2025
Anti-inflammatory effect of curcumin on neurological disorders: a narrative review.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Natural compounds as multitarget agents in Alzheimer's diseases: evidence fromFrontiers in pharmacology · 2026Pooled it
- Polyphenols at the Helm: Excited State Photophysics and Mechanistic Insights Into Protein-Aggregation Inhibition Through Ultrafast Studies.Chemistry, an Asian journal · 2026Article
- Review
- Curcumin in Alzheimer's Disease: From Mechanistic Insights to Translational Challenges and Emerging Curcuminoid Strategies.International journal of molecular sciences · 2026Review
- Shared gene signatures and biochemical regulatory networks linking Parkinson's disease and ulcerative colitis.NPJ Parkinson's disease · 2026Article
- Targeted Drug Delivery in Animal Models of Demyelination: The Role of Plant-Based Nanoparticles with a Focus on Multiple Sclerosis.Molecular neurobiology · 2026Review
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
- Stage-Dependent Function of Astrocytes in Alzheimer's Disease: A Review.Neuroscience insights · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroinflammation arises from the synergistic interplay of multiple inflammatory mediators and is pathologically associated with various neurological disorders. These conditions are complex, multifactorial diseases characterized by dynamic interactions between chronic neuroinflammation, oxidative stress, and progressive neuronal degeneration. Curcumin, a naturally occurring polyphenolic compound, exhibits significant pharmacological activity in anti-inflammatory processes and immune regulation. Within neuroinflammatory pathologies, microglial cells are crucial effector cells as they can secrete inflammatory mediators. Emerging evidence suggests that these resident immune cells are the primary site of the biological activity of curcumin in the central nervous system. The compound demonstrates multimodal regulatory effects, including modulation of key signaling pathways (NF-κB, NLRP3 inflammasome, and Nrf2) and upregulation of anti-inflammatory cytokines (TGF-β and interleukin-10), collectively contributing to the neuroinflammatory suppression effect of curcumin. This review comprehensively analyzed the therapeutic potential of curcumin in neuroinflammation and explored its clinical prospects for neurological disease intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.